Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Science

Volumn 324, Issue 5933, 2009, Pages 1457-1461

  Olive, Kenneth P ^a   Jacobetz, Michael A ^a   Davidson, Christian J ^b   Gopinathan, Aarthi ^a,b   McIntyre, Dominick ^a   Honess, Davina ^a   Madhu, Basetti ^a   Goldgraben, Mae A ^a   Caldwell, Meredith E ^a   Allard, David ^a   Frese, Kristopher K ^a   DeNicola, Gina ^a,b   Feig, Christine ^a   Combs, Chelsea ^b   Winter, Stephen P ^a   Ireland Zecchini, Heather ^a   Reichelt, Stefanie ^a   Howat, William J ^a   Chang, Alex ^c   Dhara, Mousumi ^c   Wang, Lifu ^b,d   Rückert, Felix ^e   Grützmann, Robert ^e   Pilarsky, Christian ^e   Izeradjene, Kamel ^f   Hingorani, Sunil R ^f   Huang, Pearl ^g   Davies, Susan E ^h   Plunkett, William ⁱ   Egorin, Merrill ^j   Hruban, Ralph H ^c   Whitebread, Nigel ^k   McGovern, Karen ^k   Adams, Julian ^k   Iacobuzio Donahue, Christine ^c   Griffiths, John ^a   Tuveson, David A ^a   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^k Infinity Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; CYCLOPAMINE; DOXORUBICIN; GADOLINIUM; GEMCITABINE; IPI 926; LIPOSOME; MESSENGER RNA; PENTETIC ACID; PLANT LECTIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

BIOCHEMISTRY; CANCER; CHEMOTHERAPY; CYTOLOGY; DRUG; RODENT; TUMOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; ENDOTHELIUM CELL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; LIVER METASTASIS; MICROARRAY ANALYSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS TUMOR; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TOMATO; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STROMAL CELLS; VERATRUM ALKALOIDS;

ERINACEIDAE; MUS;

EID: 67149143399     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1171362     Document Type: Article

References (29)

1. D. Li, K. Xie, R. Wolff, J. L. Abbruzzese, Lancet 363, 1049 (2004).
2. H. A. Burris III et al., J. Clin. Oncol. 15, 2403 (1997).
3. M. Tempero et al., J. Clin. Oncol. 21, 3402 (2003).
4. C. J. Bruns et al., Int. J. Cancer 102, 101 (2002).
5. T. Shimamura et al., Cancer Res. 67, 9903 (2007).
6. A. Verma et al., Clin. Cancer Res. 14, 2476 (2008).
7. J. X. Duan et al., J. Med. Chem. 51, 2412 (2008).
8. D. Melisi et al., Mol. Cancer Ther. 7, 829 (2008).
9. R. M. Schultz et al., Oncol. Res. 5, 223 (1993).
10. S. R. Hingorani et al., Cancer Cell 7, 469 (2005).
11. R. H. Hruban et al., Cancer Res. 66, 95 (2006).
12. N. Cook, K. P. Olive, K. Frese, D. A. Tuveson, Methods Enzymol. 439, 73 (2008).
13. Materials and methods are available as supporting material on Science Online.
14. J. L. Abbruzzese et al., J. Clin. Oncol. 9, 491 (1991).
15. O. Tredan, C. M. Galmarini, K. Patel, I. F. Tannock, J. Natl. Cancer Inst. 99, 1441 (2007).
16. A. I. Minchinton, I. F. Tannock, Nat. Rev. Cancer 6, 583 (2006).
17. M. J. Egorin, R. C. Hildebrand, E. F. Cimino, N. R. Bachur, Cancer Res. 34, 2243 (1974).
18. R. L. Yauch et al., Nature 455, 406 (2008).
19. J. M. Bailey et al., Clin. Cancer Res. 14, 5995 (2008).
20. S. P. Thayer et al., Nature 425, 851 (2003).
21. H. Tian et al., Proc. Natl. Acad. Sci. U.S.A. 106, 4254 (2009).
22. O. Nolan-Stevaux et al., Genes Dev. 23, 24 (2009).
23. J. I. Johnson et al., Br. J. Cancer 84, 1424 (2001).
24. A. Sofuni et al., J. Gastroenterol. 40, 518 (2005).
25. H. Sakamoto et al., Ultrasound Med. Biol. 34, 525 (2008).
26. E. Van Cutsem et al., J. Clin. Oncol. 27, 2231 (2009).
27. R. Pola et al., Nat. Med. 7, 706 (2001).
28. S. J. Langer, A. P. Ghafoori, M. Byrd, L. Leinwand, Nucleic Acids Res. 30, 3067 (2002).
29. We thank the animal care staffs of the Cambridge Research Institute (CRI), University of Pennsylvania Translational Research Labs, FHCRC, and University Hospital Dresden as well as the histology and genomics cores at CRI, and P. Calses for technical assistance. We also thank B. Bean of Transnetyx Inc. for developing high-throughput genotyping assays for the KPC mice. This research was supported by the Lustgarten Foundation, the University of Cambridge and Cancer Research UK, The Li Ka Shing Foundation and Hutchison Whampoa Limited, the National Institute for Health Research Cambridge Biomedical Research Centre, and NIH (grants CA101973, CA111292, CA084291, and CA105490 to D.A.T.; K08 CA106610 to C.I.-D.; and CA15704 and CA114028 to S.R.H.). S.R.H. was supported by a grant from the Mead Foundation. Preliminary studies were supported by a grant from the University of Pennsylvania/GlaxoSmithKline Alternative Drug Discovery Initiative. K.P.O. and K.K.F. were supported by NIH under Ruth L. Kirschstein National Research Service Awards F32CA123939-02 (K.P.O.) and F32CA123887-01 (K.K.F.). In addition to being an officer of Infinity Pharmaceuticals, J.A. is a member of the Senior Advisory Boards of Constellation Pharma and Auspex Pharma. Cancer Research Technology, which is associated with Cancer Research UK, has filed a U.S. provisional patent application related to this work.